HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Halfdanarson, T. R Articles by Petersen, G. M Search for Related Content PubMed PubMed Citation Articles by Halfdanarson, T. R Articles by Petersen, G. M

Division of Oncology, Department of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA¹ Department of Surgery, Rochester, Minnesota, USA² Department of Health Sciences Research, Rochester, Minnesota, USA

(Correspondence should be addressed to T R Halfdanarson who is now at Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, Iowa 52242, USA; Email: thorvardur-halfdanarson{at}uiowa.edu)

Pancreatic endocrine tumors (PETs) are uncommon tumors with an annual incidence <1 per 100 000 person-years in the general population. The PETs that produce hormones resulting in symptoms are designated as functional. The majority of PETs are non-functional. Of the functional tumors, insulinomas are the most common, followed by gastrinomas. The clinical course of patients with PETs is variable and depends on the extent of the disease and the treatment rendered. Patients with completely resected tumors generally have a good prognosis, and aggressive surgical therapy in patients with advanced disease may also prolong survival. The epidemiology, prognosis, and established and novel prognostic markers of PETs are reviewed.

This article has been cited by other articles:

				E. Dejeux, R. Olaso, B. Dousset, A. Audebourg, I. G Gut, B. Terris, and J. Tost Hypermethylation of the IGF2 differentially methylated region 2 is a specific event in insulinomas leading to loss-of-imprinting and overexpression Endocr. Relat. Cancer, September 1, 2009; 16(3): 939 - 952. [Abstract] [Full Text] [PDF]

				M. Mei, D. Deng, T.-H. Liu, X.-T. Sang, X. Lu, H.-D. Xiang, J. Zhou, H. Wu, Y. Yang, J. Chen, et al. Clinical Implications of Microsatellite Instability and MLH1 Gene Inactivation in Sporadic Insulinomas J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3448 - 3457. [Abstract] [Full Text] [PDF]

				F. Ehehalt, H. D. Saeger, C. M. Schmidt, and R. Grutzmann Neuroendocrine Tumors of the Pancreas Oncologist, May 1, 2009; 14(5): 456 - 467. [Abstract] [Full Text] [PDF]